Clinical Trial Update: Randomized, Controlled Study Evaluating CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease [Phase 2]

View source ↗

Summary

A Phase 2 randomized, controlled trial evaluating CERE-110 in subjects with mild to moderate Alzheimer's disease has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• CERE-110

Snippet

Sponsor: Sangamo Therapeutics | Conditions: Alzheimer's Disease | Phase 2 | Status: COMPLETED